Stocks-RVNC-Revance Therapeutics Inc

RVNC Revance Therapeutics Inc

32.13 0.98 (3.15%)
Delayed Prices By NASDAQ, in USD Market Closed
Invest
Stocks-RVNC-Revance Therapeutics Inc
RVNC Revance Therapeutics Inc
Invest

Overview

Prev Close 32.13
Day's Range 30.30 - 32.31
52 Week Range 11.24 - 36.35
Average Volume (3M) 1.63M
1-Year Return 68.39%
Beta1.2456
Market Cap 2.66B
P/E Ratio-6.68
Revenue132.57M
EPS-4.8129
Dividend (Yield) 0 (0%)
1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max
Created with Highcharts 4.2.7 /Highstock 4.2.705/10/202215/12/202228/02/202320.0022.5025.0027.5030.0032.5035.0037.50
Chart times in UTC
Sector
Health Technology
Industry
Pharmaceuticals Major
CEO
Mark J. Foley
Employees
534

FINANCIAL SUMMARY

For the quarter ended 31/12/2022, Revance Therapeutics Inc's revenues increased by 72.05% and amounted to 49.92M. Net income decreased by 72.33% to -145.95M. Net assets decreased by 91.35% to 12.60M and EPS decreased from -1.17 to -1.82.
RVNC's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterl